| 15.25 0 (0%) | 11-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Aerie Pharmaceuticals, Inc. operates as a pharmaceutical enterprise focused on the discovery, development, and commercialization of ophthalmic treatments for the U.S. market. The company's therapeutic scope includes open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration. Its commercialized portfolio features Rhopressa, a once-daily eye drop designed to lower elevated intraocular pressure (IOP) for patients with open-angle glaucoma or ocular hypertension. Also available is Rocklatan, a daily fixed-dose combination of Rhopressa and latanoprost, which similarly works to reduce IOP in individuals with these conditions. In its development pipeline, Aerie is advancing AR-15512 to address the symptoms and signs of dry eye, alongside AR-1105 and AR-14034 SR, which are sustained-release implants targeting various retinal diseases. The company also engages in a collaborative research, development, and licensing agreement with DSM Biomedical. Established in 2005, Aerie Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
Thu, 03 Nov 2022
Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results - Business Wire
Tue, 04 Oct 2022
10 Best-Performing Small-Cap Stocks of 2022 - Yahoo Finance
Tue, 23 Aug 2022
Aerie Pharmaceuticals Stock Surges as Alcon to Buy Eye Care Firm in $770 Million Deal - Barron's
Thu, 04 Aug 2022
Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update - Business Wire
Fri, 18 Mar 2022
Aerie Pharmaceuticals Appoints Peter Lang as CFO - citybiz
Thu, 16 Dec 2021
Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer - citybiz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|